DANIEL LEUNG to Hepatitis C, Chronic
This is a "connection" page, showing publications DANIEL LEUNG has written about Hepatitis C, Chronic.
Connection Strength
2.009
-
Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper. J Pediatr Gastroenterol Nutr. 2020 09; 71(3):407-417.
Score: 0.529
-
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 07; 37(7):3299-3310.
Score: 0.519
-
Hepatitis B and C. Clin Liver Dis. 2018 11; 22(4):703-722.
Score: 0.460
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
Score: 0.170
-
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021 07; 74(1):19-27.
Score: 0.140
-
Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2020 05; 70(5):711-717.
Score: 0.129
-
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology. 2025 Jan 01; 81(1):358-379.
Score: 0.042
-
NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012 Jun; 54(6):838-55.
Score: 0.019